Article Text

Download PDFPDF
EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1β in synovial fibroblasts
  1. R Largo,
  2. I Díez-Ortego,
  3. O Sanchez-Pernaute,
  4. M J López-Armada,
  5. M A Alvarez-Soria,
  6. J Egido,
  7. G Herrero-Beaumont
  1. Bone and Joint Research Unit, Fundación Jiménez Díaz, Autonoma University, Madrid, Spain
  1. Correspondence to:
    Dr G Herrero-Beaumont
    Rheumatology Department, Fundación Jiménez Díaz, Avenida Reyes Católicos 2, 28040 Madrid, Spain, gherrerofjd.es

Abstract

Background: Besides its proinflammatory properties, prostaglandin E2 (PGE2) acts as a regulator of the expression of inducible genes. Inhibition of PGE2 synthesis might thus result in a paradoxical deleterious effect on inflammation.

Objective: To examine the effect of PGE2 on monocyte chemoattractant protein-1 (MCP-1) expression in cultured synovial fibroblasts (SF) stimulated with interleukin (IL)1β.

Methods: MCP-1 expression was assessed in SF stimulated with IL1β in the presence of PGE2 or different NSAIDs by RT-PCR or northern blot and immunocytochemistry. Expression of cyclo-oxygenase (COX) isoforms was studied by western blot techniques. The role of PGE2 receptors (EP) in PGE2 action was assessed employing EP receptor subtype-specific agonists.

Results: PGE2 significantly inhibited IL1β induced MCP-1 expression in SF in a dose dependent manner. IL1β increased COX-2 and did not alter COX-1 synthesis in SF. 11-Deoxy-PGE1, an EP2/EP4 agonist, reproduced PGE2 action on MCP-1 expression. Butaprost, a selective EP2 agonist, was less potent than PGE2. Sulprostone, an EP1/EP3 agonist, had no effect on IL1β induced MCP-1 expression. Inhibition of endogenous PGE2 synthesis by NSAIDs further enhanced MCP-1 mRNA expression in IL1β stimulated SF, an effect prevented by addition of exogenous PGE2.

Conclusion: Activation of EP2/EP4 receptors down regulates the expression of MCP-1 in IL1β stimulated SF, while PGE2 pharmacological inhibition cuts off this signalling pathway and results in a superinduction of MCP-1 expression. The data suggest that NSAIDs may intercept a natural regulatory circuit controlling the magnitude of inflammation, which questions their continuous administration in inflammatory joint diseases.

  • AC, adenylate cyclase
  • cAMP, cyclic adenosine monophosphate
  • COX, cyclo-oxygenase
  • DCF, diclofenac
  • EMSA, electrophoretic mobility shift assay
  • GAPDH, glyceraldehyde-3′-phosphate dehydrogenase
  • IL, interleukin
  • MCP-1, monocyte chemoattractant peptide-1
  • MXC, meloxicam
  • NSAIDs, non-steroidal anti-inflammatory drugs
  • PGE2, prostaglandin E2
  • RT-PCR, reverse transcription-polymerase chain reaction
  • SF, synovial fibroblasts
  • EP2/EP4 receptors
  • monocyte chemoattractant protein-1
  • prostaglandin E2
  • synovial cells

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.